Moderna COVID-19 vaccine tied to lower adverse event risk in older adults
Aug 11, 2023
The mRNA-1273 vaccine also was tied to greater protection against COVID-19 in older adults.
FDA advisers say next round of COVID-19 booster shots should target an XBB Variant
Jun 15, 2023
Protection against the original strain of the virus will be dropped from the updated vaccines as it could contribute to lower vaccine efficacy against newer strains.
FDA approves first RSV vaccine
May 03, 2023
Arexvy was ~82% effective in preventing RSV-induced lower respiratory tract infections in adults aged 60 or more years.
RSVpreF safe, effective for preventing respiratory syncytial virus illness in seniors
Apr 10, 2023
The findings seen in phase 3 trial of adults aged 60 years and older receiving a single intramuscular injection of RSVpreF vaccine.
Age, cancer type affect COVID-19 vaccine uptake in cancer patients
Mar 16, 2023
Higher rates of vaccination were seen in older patients; lower rates were seen for metastatic solid tumors, with comorbidities.
FDA panel backs second RSV vaccine for older Americans
Mar 02, 2023
In a two-part vote, the panel voted 10-to-2 in favor of the vaccine’s safety and unanimously on the shot’s effectiveness.
FDA panel backs Pfizer RSV vaccine for older Americans
Mar 01, 2023
Pfizer has reported that its vaccine would reduce risk from RSV by as much as 86%.
Single dose of RSV vaccine prevents acute respiratory infection in seniors
Feb 17, 2023
High vaccine efficacy was seen against RSV A and B subtypes, across age groups among those aged 60 years and older, and for those with coexisting conditions.
Ad26.RSV.preF-RSV preF protein vaccine immunogenic in seniors
Feb 16, 2023
Vaccination results in lower RSV-mediated lower respiratory tract disease meeting one of three definitions.
COVID-19 vaccine protection lasts at least six months after second dose
Feb 07, 2023
Vaccine effectiveness against death was lower for patients aged 80 years and older.